2023年11月1日 · Calcium channel blockers (CCBs) are split into two categories, dihydropyridines (DHP), such as amlodipine and nicardipine, and non-dihydropyridines (non-DHP), such as verapamil and diltiazem.

2023年2月6日 · Verapamil is a non-dihydropyridine calcium channel blocker. Calcium channel blockers inhibit the entry of calcium ions into the slow L-type calcium channels in the myocardium and vascular smooth muscle during depolarization.

2024年2月22日 · CCBs are often classified into 2 major categories—non-dihydropyridines or dihydropyridines. The non-dihydropyridines include verapamil, classified as a phenylalkylamine, and diltiazem, categorized as a benzothiazepine.

Compared with certain other L-type calcium channel blockers (for example those of the phenylalkylamine class such as verapamil) that have significant action at the heart, the dihydropyridine calcium channel blockers lower blood pressure mainly by relaxing the smooth muscle of the blood vessel walls.

High doses of dihydropyridine calcium channel blockers often cause edema, headache, flushing and tachycardia; high doses of verapamil can cause constipation. Diltiazem and verapamil have important drug interaction with digoxin and cyclosporine, among others.

Combined dihydropyridine/nondihydropyridine CCB therapy has been used effectively in hypertensive patients with additive and sometimes synergistic BP‐reducing properties. 9, 10, 11 Saseen and colleagues 9 found that the addition of either verapamil or diltiazem significantly raised nifedipine blood levels, and this pharmacokinetic interaction ...

1997年1月1日 · Verapamil has a unique role among the calcium channel antagonists in the management of supraventricular arrhythmias. Normal conduction through the AV node is dependent on calcium entry into the conducting tissue cells for depolarisation. Verapamil reduces calcium entry and thus slows AV conduction.

Dihydropyridine CCBs should not be used as monotherapy in hypertensive patients with chronic kidney disease and proteinuria. 100 Verapamil or diltiazem in combination with other agents are useful therapies in the proteinuric chronic kidney disease patient. 101

Calcium channel blockers (CCBs), which include both dihydropyridines such as nifedipine and amlodipine and non-dihydropyridines (verapamil and diltiazem), are among the most widely prescribed agents for the management of essential hypertension.

Dihydropyridine (DHP) calcium channel blockers are derived from the molecule dihydropyridine and often used to reduce systemic vascular resistance and arterial pressure.